At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Paclitaxel Albumin-Stabilized Nanoparticle Formulation for Recurrent Non-Small Cell Lung Carcinoma and Stage IV Non-Small Cell Lung Cancer. Completed, enrolled 26 participants across 12 sites.
Detailed Summary
This research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer. Doctors want to know if Abraxane is safe and effective in treating patients with lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) and epidermal growth factor receptor (EGFR) mutations.
Study Details
Timeline
Interventions
Correlative studies
Given IV